J Gralow
Overview
Explore the profile of J Gralow including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
352
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de Azambuja E, Piccart-Gebhart M, Fielding S, Townend J, Hillman D, Colleoni M, et al.
ESMO Open
. 2024 Oct;
9(11):103938.
PMID: 39418883
Background: Dual anti-human epidermal growth factor receptor 2 (HER2) blockade has improved the outcomes of patients with early and metastatic HER2-positive breast cancer. Here we present the final 10-year analysis...
2.
Spraggs C, Parham L, Briley L, Warren L, Williams L, Fraser D, et al.
Pharmacogenomics J
. 2017 Aug;
18(3):480-486.
PMID: 28786423
HLA-DRB1*07:01 allele carriage was characterised as a risk biomarker for lapatinib-induced liver injury in a large global study evaluating lapatinib, alone and in combination with trastuzumab and taxanes, as adjuvant...
3.
Schneider B, Li L, Shen F, Miller K, Radovich M, ONeill A, et al.
Br J Cancer
. 2014 Aug;
111(6):1241-8.
PMID: 25117820
Background: Bevacizumab has broad anti-tumour activity, but substantial risk of hypertension. No reliable markers are available for predicting bevacizumab-induced hypertension. Methods: A genome-wide association study (GWAS) was performed in the...
4.
Cheng H, Ballman K, Vassilakopoulou M, Dueck A, Reinholz M, Tenner K, et al.
Br J Cancer
. 2014 Aug;
111(6):1065-71.
PMID: 25117817
Background: Epidermal growth factor receptor (EGFR) has been hypothesised to modulate the effectiveness of anti-HER2 therapy. We used a standardised, quantitative immunofluorescence assay and a novel EGFR antibody to evaluate...
5.
Zielinski C, Gralow J, Martin M
Ann Oncol
. 2010 Mar;
21(11):2145-2152.
PMID: 20332132
While 'targeted' drugs often take centre stage when considering developments in breast cancer, improved understanding, administration and use of chemotherapeutic agents also contribute to better outcomes for women with metastatic...
6.
Aapro M, Abrahamsson P, Body J, Coleman R, Colomer R, Costa L, et al.
Ann Oncol
. 2007 Oct;
19(3):420-32.
PMID: 17906299
Bisphosphonates (BP) prevent, reduce, and delay cancer-related skeletal complications in patients, and have substantially decreased the prevalence of such events since their introduction. Today, a broad range of BP with...
7.
Tait D, Jensen R, Holt J, Johnson D, Gralow J, King M
Breast Dis
. 2005 Feb;
10(1-2):89-98.
PMID: 15687552
As an initial step toward gene therapy for ovarian cancer, we conducted a Phase 1 trial to assess the pharmacokinetics and toxicity of intraperitoneal BRCA1sv retroviral vector therapy. Gene transfer...
8.
Wilkie D, Huang H, Berry D, Schwartz A, Lin Y, Ko N, et al.
Fam Community Health
. 2001 Sep;
24(3):48-62.
PMID: 11563944
This study evaluated the feasibility of an innovative computerized symptom assessment tool, SymptomReport, and a computerized, tailored education tool, SymptomConsult, in a sample of 41 outpatients with cancer. After patients...
9.
Bowen D, McTiernan A, Burke W, Powers D, PRUSKI J, Durfy S, et al.
Cancer Epidemiol Biomarkers Prev
. 1999 Jul;
8(7):581-5.
PMID: 10428194
Recent scientific breakthroughs in the genetics of breast cancer may have had effects on women's perceptions of risk and subsequent worry about breast cancer. Here, we present the rates of...
10.
McTiernan A, Ulrich C, Kumai C, Bean D, Schwartz R, Mahloch J, et al.
Cancer Epidemiol Biomarkers Prev
. 1998 Jun;
7(6):477-81.
PMID: 9641491
To assess the feasibility of an exercise-diet intervention in sedentary, overweight breast cancer patients, we conducted a pilot 8-week intervention. Recruitment letters and interest surveys were sent to 99 stage...